DK1140969T3 - Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf - Google Patents

Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf

Info

Publication number
DK1140969T3
DK1140969T3 DK99965256T DK99965256T DK1140969T3 DK 1140969 T3 DK1140969 T3 DK 1140969T3 DK 99965256 T DK99965256 T DK 99965256T DK 99965256 T DK99965256 T DK 99965256T DK 1140969 T3 DK1140969 T3 DK 1140969T3
Authority
DK
Denmark
Prior art keywords
methods
ctgf
growth factor
connective tissue
tissue growth
Prior art date
Application number
DK99965256T
Other languages
English (en)
Inventor
Gary R Grotendorst
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Application granted granted Critical
Publication of DK1140969T3 publication Critical patent/DK1140969T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
DK99965256T 1998-12-14 1999-12-14 Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf DK1140969T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11224198P 1998-12-14 1998-12-14
US11224098P 1998-12-14 1998-12-14
PCT/US1999/029652 WO2000035936A1 (en) 1998-12-14 1999-12-14 Connective tissue growth factor fragments and methods and uses thereof

Publications (1)

Publication Number Publication Date
DK1140969T3 true DK1140969T3 (da) 2007-09-17

Family

ID=26809725

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99965256T DK1140969T3 (da) 1998-12-14 1999-12-14 Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf

Country Status (16)

Country Link
US (3) US6492129B1 (da)
EP (2) EP1140969B1 (da)
JP (2) JP4634614B2 (da)
KR (2) KR100664625B1 (da)
CN (3) CN1187370C (da)
AT (2) ATE391724T1 (da)
AU (3) AU773278B2 (da)
CA (2) CA2354422A1 (da)
CY (1) CY1108860T1 (da)
DE (2) DE69938507T2 (da)
DK (1) DK1140969T3 (da)
ES (2) ES2304811T3 (da)
HK (2) HK1041268B (da)
MX (1) MXPA01005949A (da)
PT (1) PT1140969E (da)
WO (2) WO2000035936A1 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026299B2 (en) 1994-07-12 2006-04-11 Human Genome Sciences, Inc. Connective tissue growth factor-2
EP0804562B1 (en) 1994-07-12 2002-10-09 Human Genome Sciences, Inc. Connective tissue growth factor-2
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
AU773278B2 (en) * 1998-12-14 2004-05-20 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
EP1373299A4 (en) * 2000-07-11 2005-01-19 Human Genome Sciences Inc Connective tissue GROWTH FACTOR-2
EP1434993B1 (en) * 2001-09-18 2013-04-24 Fibrogen, Inc. Methods of assaying connective tissue growth factor
CN1604783A (zh) * 2001-10-26 2005-04-06 里伯药品公司 通过rna干扰治疗纤维化疾病的药物
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
CN1602207A (zh) * 2001-12-11 2005-03-30 法布罗根股份有限公司 抑制眼病理过程的方法
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US20050153395A1 (en) * 2003-09-29 2005-07-14 Children's Hospital Inc. Unique integrin binding site in connective tissue growth factor (CTGF)
EP1687410A4 (en) 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc ANTISENSE OLIGONUCLEOTIDES OPTIMIZED TO TARGET THE KIDNEY
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
DE602005008013D1 (de) 2004-02-11 2008-08-21 Fibrogen Inc Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
CN1929861B (zh) * 2004-02-11 2010-12-29 法布罗根股份有限公司 Ctgf作为糖尿病肾病的治疗靶点
US20050271670A1 (en) 2004-04-28 2005-12-08 Spong Suzanne M Treatments for cancer
WO2005116194A1 (ja) * 2004-05-25 2005-12-08 Riken 試験管内筋繊維形成のための筋芽細胞又は筋芽細胞様細胞培養法
EP1692935A1 (en) * 2005-02-22 2006-08-23 Boehringer Ingelheim International GmbH Transgenic animal as a model for human pulmonary disease
NZ563493A (en) 2005-05-05 2010-10-29 Fibrogen Inc Use of an anti-CTGF agent for the treatment of a vascular dysfunction in a patient
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
PT2289909E (pt) 2005-11-30 2015-02-10 Abbvie Inc Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
WO2008027288A2 (en) 2006-08-30 2008-03-06 The Trustees Of Columbia University In The City Of New York Treatment for craniosynostosis by growth factor delivery
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8617877B2 (en) * 2007-11-02 2013-12-31 The Johns Hopkins University Cardiac stem cell and myocyte secreted paracrine factors
KR101877698B1 (ko) * 2008-08-25 2018-07-12 엑스칼리아드 파마슈티컬즈, 인코포레이티드 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
WO2010027830A2 (en) * 2008-08-25 2010-03-11 Excaliard Pharmaceuticals, Inc. Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases
US8664189B2 (en) 2008-09-22 2014-03-04 Rxi Pharmaceuticals Corporation RNA interference in skin indications
WO2011002525A1 (en) 2009-07-02 2011-01-06 Fibrogen, Inc. Methods for treatment of muscular dystrophy
US20120244169A1 (en) 2009-11-06 2012-09-27 Fibrogen, Inc. Treatment for Radiation-Induced Disorders
CN105131067B (zh) 2010-03-24 2019-02-19 雷克西制药公司 皮肤与纤维化症候中的rna干扰
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
KR101249041B1 (ko) 2010-04-28 2013-03-29 포항공과대학교 산학협력단 결합조직 성장인자를 이용한 약학적 조성물
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
WO2012061811A2 (en) 2010-11-05 2012-05-10 Fibrogen, Inc. Treatment method for lung remodeling diseases
WO2012100262A1 (en) 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
MX365647B (es) * 2011-02-02 2019-06-10 Excaliard Pharmaceuticals Inc El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.
JP6040943B2 (ja) * 2011-12-22 2016-12-07 アステラス製薬株式会社 新規抗ヒトｃｔｇｆ抗体
US9480449B2 (en) 2012-05-03 2016-11-01 Fibrogen, Inc. Methods for treating idiopathic pulmonary fibrosis
US9132171B2 (en) 2012-05-23 2015-09-15 Wisconsin Alumni Research Foundation Test of insulin as a drug to reduce restenosis of vessels
US9631013B2 (en) 2014-01-28 2017-04-25 Fibrogen, Inc. Therapeutic method for pancreatic cancer
CA2986926A1 (en) 2015-06-15 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating affective disorders
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN111424035A (zh) * 2020-04-13 2020-07-17 西南大学 基于家蚕丝腺表达具有生物学活性的人结缔组织生长因子的方法及其产品和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US392024A (en) * 1888-10-30 Jjett
US4906742A (en) * 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
FR2678283A1 (fr) * 1991-06-25 1992-12-31 Centre Nat Rech Scient Sequences de nucleotides, sequences d'acides amines correspondantes, et leurs applications biologiques.
US5770209A (en) * 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5596090A (en) * 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
EP0804562B1 (en) * 1994-07-12 2002-10-09 Human Genome Sciences, Inc. Connective tissue growth factor-2
US5789389A (en) * 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5688915A (en) 1995-06-01 1997-11-18 The University Of Medicine And Dentistry Of New Jersey Long term maintenance of lymphocytes in vitro
CA2220912A1 (en) * 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
US5876730A (en) * 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
AU1682699A (en) * 1997-12-25 1999-07-19 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
WO1999042583A1 (en) * 1998-02-20 1999-08-26 Zymogenetics, Inc. Connective tissue growth factor homologs
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
US6348329B1 (en) * 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
AU773278B2 (en) * 1998-12-14 2004-05-20 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies

Also Published As

Publication number Publication date
KR20010101207A (ko) 2001-11-14
ES2288321T3 (es) 2008-01-01
DE69938507T2 (de) 2009-06-10
CN1334819A (zh) 2002-02-06
MXPA01005949A (es) 2002-09-18
US6492129B1 (en) 2002-12-10
KR20010101194A (ko) 2001-11-14
DE69936315T2 (de) 2008-02-14
EP1140969B1 (en) 2007-06-13
DE69936315D1 (de) 2007-07-26
US20030180300A1 (en) 2003-09-25
AU2004205171B2 (en) 2007-08-09
JP2002532084A (ja) 2002-10-02
CN1187370C (zh) 2005-02-02
US20100190838A1 (en) 2010-07-29
AU775391B2 (en) 2004-07-29
WO2000035939A2 (en) 2000-06-22
HK1041005A1 (en) 2002-06-28
ATE364617T1 (de) 2007-07-15
EP1140969A1 (en) 2001-10-10
DE69938507D1 (en) 2008-05-21
KR100664626B1 (ko) 2007-01-04
EP1140964A4 (en) 2003-06-18
JP4722290B2 (ja) 2011-07-13
WO2000035936A1 (en) 2000-06-22
ATE391724T1 (de) 2008-04-15
AU2181900A (en) 2000-07-03
HK1041005B (zh) 2007-11-09
EP1140964B1 (en) 2008-04-09
AU773278B2 (en) 2004-05-20
JP4634614B2 (ja) 2011-02-16
WO2000035939A3 (en) 2000-10-12
CA2354456A1 (en) 2000-06-22
AU2004205171A1 (en) 2004-09-16
CN1334820A (zh) 2002-02-06
EP1140964A2 (en) 2001-10-10
AU3121100A (en) 2000-07-03
HK1041268B (zh) 2009-02-27
KR100664625B1 (ko) 2007-01-04
PT1140969E (pt) 2007-08-30
CN1660911A (zh) 2005-08-31
EP1140969A4 (en) 2003-07-23
ES2304811T3 (es) 2008-10-16
JP2002532082A (ja) 2002-10-02
CY1108860T1 (el) 2014-07-02
HK1041268A1 (en) 2002-07-05
CA2354422A1 (en) 2000-06-22
US7718177B2 (en) 2010-05-18
CN1170849C (zh) 2004-10-13

Similar Documents

Publication Publication Date Title
DK1140969T3 (da) Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
CA2213533A1 (en) Resorbable extracellular matrix for reconstruction of cartilage tissue
DE693928T1 (de) Aminozucker- und glykosaminoglykanzusammensetzung zur behandlung und reparatus von bindegewebe
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
ES2165878T3 (es) Utilizacion del modafinil para el tratamiento de las apneas del sueño y trastornos de ventilacion de origen central.
ES2113857T3 (es) Composiciones osteoinductoras.
ATE259215T1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
DE69533176D1 (de) Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
CA2265508A1 (en) Bone morphogenetic protein-16 (bmp-16) compositions
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
EP1978362A3 (en) Cross beta structure comprising amyloid binding proteins and methods for detection of the cross beta structure, for modulating cross beta structures fibril formation and for modulating cross beta structure-mediated toxicity
EP0832100A4 (en) NOVEL METALLOPROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF USE
DE69711078T2 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
MX9709910A (es) Compuestos que contienen arginina e imitaciones de arginina, su uso y composiciones que los contienen.
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
TR200200278T2 (tr) Kalsilitik bileşimler
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE285794T1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
DE60232733D1 (de) Alternativ gesplicter zirkulierender gewebefaktor
RO117234B1 (ro) Fibride colagenice şi procedeu de obţinere